Imagen de Portada

Comment on “Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– IGF ‐1 axis”

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Caoxu Zhang, Qi Sun
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Diabetes, Obesity and Metabolism
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– IGF ‐1 axis: Results from an exploratory, randomized, placebo‐controlled, crossover study
por: Valeria Gutierrez de Piñeres, et al.
Publicado: (2025)

Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction
por: Yuan Li, et al.
Publicado: (2026)

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg
por: Susanne Kuckuck, et al.
Publicado: (2026)

Adipocyte‐specific IGF1R knockout activates the β‐catenin/apelin axis to combat diet‐induced obesity in male mice
por: Haoan Wang, et al.
Publicado: (2025)

Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures
por: Amit Guy, et al.
Publicado: (2024)

Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus—Results from a randomised controlled trial
por: Emilie S. Andersen, et al.
Publicado: (2025)

Real‐life use of liraglutide 3 mg in obesity management: The SAX‐RL study
por: Marc Goëau‐Brissonnière, et al.
Publicado: (2024)

Weight loss in people with type 1 diabetes over 12 months: Real‐world data comparing tirzepatide, semaglutide and liraglutide
por: Ebaa Al Ozairi, et al.
Publicado: (2025)

Combined liraglutide and metformin therapy in overweight or obese women with polycystic ovary syndrome: A systematic review and meta‐analysis
por: Jing Ling, et al.
Publicado: (2025)

Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration
por: Sofia K. Konstantinidou, et al.
Publicado: (2024)

Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Yongin Cho, et al.
Publicado: (2026)

Efficacy and safety of liraglutide in non‐alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta‐analysis
por: Weihan Kong, et al.
Publicado: (2025)

Mediterranean diet vs. the Australian guide to healthy eating ( AGHE ) on body composition and glucose metabolism: A randomized controlled trial
por: Robel Hussen Kabthymer, et al.
Publicado: (2025)

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial
por: Kelli M. Richardson, et al.
Publicado: (2025)

ACAD10 is not required for metformin's metabolic actions or for maintenance of whole‐body metabolism in C57BL / 6J mice
por: Michael J. Yew, et al.
Publicado: (2024)

The role of gut–islet axis in pancreatic islet function and glucose homeostasis
por: Qi Chen, et al.
Publicado: (2025)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
por: Stergios A. Polyzos, et al.
Publicado: (2026)

Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases
por: Tarita Murray‐Thomas, et al.
Publicado: (2025)

Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
por: Yuzi Cao, et al.
Publicado: (2025)

Biomarkers for cardiovascular–kidney metabolic syndrome: Clinical utility in diagnosis, screening, and treatment
por: Kevin Yau, et al.
Publicado: (2025)

Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
por: Jonathan Brix Winther, et al.
Publicado: (2024)

Characterization of the effect of naltrexone/bupropion on body composition
por: Vanessa Tardio, et al.
Publicado: (2025)

A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
por: Nadine Beetz, et al.
Publicado: (2024)

Individual and joint associations of obesity and metabolic health parameters on arterial stiffness: Evidence from the UK Biobank
por: Roshan A. Ananda, et al.
Publicado: (2024)

IDOL alleviates the body weight by upregulating UCP ‐1 in mice
por: Hua Guan, et al.
Publicado: (2025)

Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
por: Danna M. Breen, et al.
Publicado: (2025)

Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
por: Stergios A. Polyzos, et al.
Publicado: (2024)

The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials
por: Rachelle Haber, et al.
Publicado: (2024)

A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II
por: Snezana Milanovic, et al.
Publicado: (2025)

Hypothalamic RASA1 /Ras/ AKT / GnRH axis reprogramming mediates GLP ‐ 1RA 's central rescue of PCOS HPG dysfunction
por: Linlin Yang, et al.
Publicado: (2025)

Role of protein arginine methyltransferase 1 in obesity‐related metabolic disorders: Research progress and implications
por: Xiaolei Xuan, et al.
Publicado: (2024)

Effects of home‐based exergaming on cardio‐metabolic and cognitive health in physically inactive individuals
por: Andreas Melmer, et al.
Publicado: (2024)

The effects of antihypertensive drugs on glucose metabolism
por: Zhe Li, et al.
Publicado: (2024)

Investigating the common genetic architecture and causality of metabolic disorders with neurodegenerative diseases
por: Hao Hong, et al.
Publicado: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
por: Ruoyang Jiao, et al.
Publicado: (2024)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
por: Chih‐Yuan Wang
Publicado: (2026)

TEAD1 , MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population
por: Yingying Wu, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
por: Amanda R. Purcell, et al.
Publicado: (2025)

Mediating role of inflammatory biomarkers in the causal effect of body composition on glycaemic traits and type 2 diabetes
por: Liwan Fu, et al.
Publicado: (2024)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
por: Tommaso Bucci, et al.
Publicado: (2025)